Literature DB >> 27156045

Episodic oral antibiotic use in CF: Discordance between the electronic medical record and self-report.

Lindsay J Caverly1, Tanner J Caverly2, Linda M Kalikin3, Bridget K Foster3, Richard H Simon4, John J LiPuma3.   

Abstract

BACKGROUND: Accurate accounting of antibiotic use is necessary for studies comparing the CF airway microbiota across clinically relevant disease states. While poor adherence to chronic therapies is well described for individuals with CF, use patterns of episodic oral antibiotics are less clear.
METHODS: Eleven individuals with CF completed daily questionnaires regarding antibiotic use for a mean of 458days. Self-report of episodic oral antibiotic use was compared to antibiotic prescription data in the electronic medical record (EMR).
RESULTS: Self-reported use of episodic oral antibiotics differed from EMR data an average of 8.3% of days per subject. The majority of these discrepancies were due to self-reported use of oral antibiotics outside of the EMR-documented dates of antibiotic prescription.
CONCLUSIONS: Discrepancies exist between self-reported use of episodic oral antibiotics and EMR data that have implications for studies of the CF airway microbiota.
Copyright © 2016 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adherence; Antibiotics; Microbiome

Mesh:

Substances:

Year:  2016        PMID: 27156045      PMCID: PMC5014681          DOI: 10.1016/j.jcf.2016.04.009

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  15 in total

1.  Analysis of changes in diversity and abundance of the microbial community in a cystic fibrosis patient over a multiyear period.

Authors:  Joshua R Stokell; Raad Z Gharaibeh; Timothy J Hamp; Malcolm J Zapata; Anthony A Fodor; Todd R Steck
Journal:  J Clin Microbiol       Date:  2014-11-12       Impact factor: 5.948

2.  Changes in cystic fibrosis airway microbiota at pulmonary exacerbation.

Authors:  Lisa A Carmody; Jiangchao Zhao; Patrick D Schloss; Joseph F Petrosino; Susan Murray; Vincent B Young; Jun Z Li; John J LiPuma
Journal:  Ann Am Thorac Soc       Date:  2013-06

3.  Pulmonary medication adherence and health-care use in cystic fibrosis.

Authors:  Alexandra L Quittner; Jie Zhang; Maryna Marynchenko; Pooja A Chopra; James Signorovitch; Yana Yushkina; Kristin A Riekert
Journal:  Chest       Date:  2014-07       Impact factor: 9.410

4.  Decade-long bacterial community dynamics in cystic fibrosis airways.

Authors:  Jiangchao Zhao; Patrick D Schloss; Linda M Kalikin; Lisa A Carmody; Bridget K Foster; Joseph F Petrosino; James D Cavalcoli; Donald R VanDevanter; Susan Murray; Jun Z Li; Vincent B Young; John J LiPuma
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-26       Impact factor: 11.205

5.  Longitudinal association between medication adherence and lung health in people with cystic fibrosis.

Authors:  Michelle N Eakin; Andrew Bilderback; Michael P Boyle; Peter J Mogayzel; Kristin A Riekert
Journal:  J Cyst Fibros       Date:  2011-03-31       Impact factor: 5.482

6.  A multi-method assessment of treatment adherence for children with cystic fibrosis.

Authors:  Avani C Modi; Crystal S Lim; Nami Yu; David Geller; Mary H Wagner; Alexandra L Quittner
Journal:  J Cyst Fibros       Date:  2006-05-05       Impact factor: 5.482

7.  A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients.

Authors:  Christopher D Sibley; Michael D Parkins; Harvey R Rabin; Kangmin Duan; Jens C Norgaard; Michael G Surette
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-23       Impact factor: 11.205

8.  Pyrosequencing reveals transient cystic fibrosis lung microbiome changes with intravenous antibiotics.

Authors:  Daniel J Smith; Alison C Badrick; Martha Zakrzewski; Lutz Krause; Scott C Bell; Gregory J Anderson; David W Reid
Journal:  Eur Respir J       Date:  2014-07-17       Impact factor: 16.671

9.  The daily dynamics of cystic fibrosis airway microbiota during clinical stability and at exacerbation.

Authors:  Lisa A Carmody; Jiangchao Zhao; Linda M Kalikin; William LeBar; Richard H Simon; Arvind Venkataraman; Thomas M Schmidt; Zaid Abdo; Patrick D Schloss; John J LiPuma
Journal:  Microbiome       Date:  2015-04-01       Impact factor: 14.650

10.  Respiratory microbiota resistance and resilience to pulmonary exacerbation and subsequent antimicrobial intervention.

Authors:  Leah Cuthbertson; Geraint B Rogers; Alan W Walker; Anna Oliver; Laura E Green; Thomas W V Daniels; Mary P Carroll; Julian Parkhill; Kenneth D Bruce; Christopher J van der Gast
Journal:  ISME J       Date:  2015-11-10       Impact factor: 10.302

View more
  3 in total

1.  Liquid Chromatography Mass Spectrometry Detection of Antibiotic Agents in Sputum from Persons with Cystic Fibrosis.

Authors:  Tara Gallagher; Stefan Riedel; Joseph Kapcia; Lindsay J Caverly; Lisa Carmody; Linda M Kalikin; Junnan Lu; Joann Phan; Matthew Gargus; Miki Kagawa; Simon W Leemans; Jason A Rothman; Felix Grun; John J LiPuma; Katrine L Whiteson
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

2.  Measures of Cystic Fibrosis Airway Microbiota during Periods of Clinical Stability.

Authors:  Lindsay J Caverly; Junnan Lu; Lisa A Carmody; Linda M Kalikin; Kerby Shedden; Kristopher Opron; Michelle Azar; Shannon Cahalan; Bridget Foster; Donald R VanDevanter; Richard H Simon; John J LiPuma
Journal:  Ann Am Thorac Soc       Date:  2019-12

3.  Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria.

Authors:  Lauren M Castner; Madsen Zimbric; Shannon Cahalan; Corey Powell; Lindsay J Caverly
Journal:  J Cyst Fibros       Date:  2021-02-19       Impact factor: 5.482

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.